Lactiga Therapeutics Raises $1.6M USD in Oversubscribed Pre-Seed Round, Secures $350k in Research Grants NORTH BRUNSWICK, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Lactiga Therapeutics, an early-stage biotechnology company focused on improving the quality of life of patients with primary...

Lactiga Continues to Build a Substantial Global Biologics Patent Portfolio PRINCETON, N.J., July 20, 2021 (GLOBE NEWSWIRE) -- Lactiga, Inc. (“Lactiga”), a biotherapeutics company advancing anti-infective biologics to prevent mucosal infections in immunodeficient patients,...

Checkmate Capital Group Completes Seed Investment in Lactiga, Inc. PRINCETON, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Lactiga, Inc. (“Lactiga”), an award-winning biotherapeutics company developing anti-infective biologics, is pleased to announce the completion of...